ASPHO24
A meta-analysis of 24 studies observed a decrease in pediatric cancer treatment abandonment after the intervention.
Palliative care facilitates communication and helps with symptom management, the researchers noted.
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
Advertisement
Around 45% of patients had a complete response after cladribine, and 31% proceeded to transplant.
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Dr. Shah’s areas of expertise include immunology and immunotherapy, rare tumors, CAR T-cell therapies, and transplantation.
Advertisement
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
The conference has a lot of great sessions, including an untraditional keynote speaker, Dr. Hastings said.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.